Bước đầu đánh giá hiệu quả Sorafenib(Nexavar) trong điều trị ung thư gan nguyên phát giai đoạn muộn

Hepatocellular cardnoma - HCC is very common in Vietnam, behind lung and stomach cancers. The cause of HCC is HBV and HCV. Sorafenib (Nexavar) is a small molecule that inhibits' tumor-cell proliferation and tumor angiogenesis. 25 patients with advanced HCC and Child-Pugh class A or B using sorafenib dose 400 800mg/day. Results: after 8 weeks treabnent, partial respone 12 percent, stable desease 80 percent, median overall survival of 5 months and 24 percent pts with overall survival more than 7 months. Side effect: diarrhea, rash, fatigue grade I, II. Grade III is less than 10 percent. Conclusion: Nexavar has improuve survival and safe for patients with advanced HCC.